FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Releases Product-Specific BE Guidance

[ Price : $8.95]

Federal Register Notice: FDA releases additional product-specific guidance on the design of bioquivalence studies to support ANDAs...

Hamburg Seeks More Pre-competitive Collaboration in R&D

[ Price : $8.95]

FDA commissioner Margaret Hamburg says that that if academia, industry, government scientists and regulators could come together m...

Ariad Leukemia Drug Approved 3 Months Ahead of Schedule

[ Price : $8.95]

Three months ahead of its user fee review date, FDA approves an Ariad Pharmaceuticals NDA for Iclusig to treat adults with two for...

Anthrax Therapy Approved by FDA

[ Price : $8.95]

FDA approves Human Genome Sciences raxibacumab injection to treat inhalational anthrax.

Regulators Policy Issues in Litigation Discussed

[ Price : $8.95]

Representatives from FDA, the Centers for Medicare and Medicaid Services and Department of Justice discuss policy considerations a...

Agency Accepts Actelion NDA for Pulmonary Arterial Hypertension

[ Price : $8.95]

FDA accepts an Actelion NDA for Opsumit (macitentan), indicated for treating patients with pulmonary arterial hypertension.

Bayer Files NDA for Prostate Cancer

[ Price : $8.95]

Bayer HealthCare submits an NDA for radium Ra 223 dichloride, an investigational compound for treating castration-resistant prosta...

FDA Rejects Jazz Pharma Petition on Xyrem REMS

[ Price : $8.95]

FDA denies a Jazz Pharmaceutical citizen petition that asked the agency to not accept any ANDA referencing its Xyrem that did not ...

Long-awaited Enrichment Studies Guidance Released

[ Price : $8.95]

FDA posts a long-awaited draft guidance on clinical trial enrichment strategies that can be used in studies to support effectivene...

FDA Clears Insulet OmniPod Insulin System

[ Price : $8.95]

FDA clears an Insulet Corp. 510(k) for the OmniPod Insulin Management System.